The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

por Guastalla III, J P, Diéras, V
Publicado 2003

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

por Cortés, J., Curigliano, G., Diéras, V.
Publicado 2014

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

por Le Tourneau, C, Servois, V, Diéras, V, Ollivier, L, Tresca, P, Paoletti, X
Publicado 2012

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

por Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Publicado 2004

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES

por Brandsma, D., Dieras, V., Altintas, S., Anders, C., Arnedos, M., Gelderblom, H., Soetekouw, P., Jager, A., van Linde, M., Aftimos, P.
Publicado 2014

Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study

por Loulergue, P, Alexandre, J, Iurisci, I, Grabar, S, Medioni, J, Ropert, S, Dieras, V, Le Chevalier, F, Oudard, S, Goldwasser, F, Lebon, P, Launay, O
Publicado 2011

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp...

por Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Publicado en Ann Oncol (2015)

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Europe...

por Dieras, V., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H., Misset, J. L., Lentz, M. A., Azli, N., Murawsky, M., Riva, A., Pouillart, P., Fumoleau, P.
Publicado 1996

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

por Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Publicado 2000

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

por Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Publicado 2014

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

por Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Publicado 2013

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

por Vincent-Salomon, A, Pierga, J-Y, Couturier, J, d'Enghien, C D, Nos, C, Sigal-Zafrani, B, Lae, M, Fréneaux, P, Diéras, V, Thiéry, J-P, Sastre-Garau, X
Publicado 2007

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

por Siegel-Lakhai, W S, Zandvliet, A S, Huitema, A D R, Tibben, M M, Milano, G, Girre, V, Diéras, V, King, A, Richmond, E, Wanders, J, Beijnen, J H, Schellens, J H M
Publicado 2008

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

por Brain, E, Isambert, N, Dalenc, F, Diéras, V, Bonneterre, J, Rezai, K, Jimenez, M, Mefti-Lacheraf, F, Cottura, E, Tresca, P, Vanlemmens, L, Mahier-Aït Oukhatar, C, Lokiec, F, Fumoleau, P
Publicado 2012

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

por Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Publicado 2005

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

por Rugo, H S, Diéras, V, Gelmon, K A, Finn, R S, Slamon, D J, Martin, M, Neven, P, Shparyk, Y, Mori, A, Lu, D R, Bhattacharyya, H, Bartlett, C Huang, Iyer, S, Johnston, S, Ettl, J, Harbeck, N
Publicado en Ann Oncol (2018)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or meta...

por Emens, L.A., Adams, S., Barrios, C.H., Dieras, V.C., Iwata, H., Loi, S., Rugo, H.S., Schneeweiss, A., Winer, E.P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Chui, S.Y., Schmid, P.
Publicado en Ann Oncol (2020)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

por Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Publicado en Breast Cancer Res Treat (2019)

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a rand...

por Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Publicado en Breast Cancer Res Treat (2017)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

por Turner, N C, Finn, R S, Martin, M, Im, S -A, DeMichele, A, Ettl, J, Diéras, V, Moulder, S, Lipatov, O, Colleoni, M, Cristofanilli, M, Lu, D R, Mori, A, Giorgetti, C, Iyer, S, Bartlett, C Huang, Gelmon, K A
Publicado en Ann Oncol (2018)